clinical trial · NCT04645966
A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants
Pfizer·phase2·terminated·n = 326
Meningococcal VaccineMenABCWYBivalent rLP2086 (60-µg Dose)Bivalent rLP2086 (120-µg Dose)BexseroProphylactic Liquid Paracetamol (PLP)NimenrixPlaceboScheduled Liquid Paracetamol (SLP)
brief summary
The aim of the study is to describe the safety, tolerability, and immunogenicity of MenABCWY in healthy infants 2 and 6 months of age.
started
Nov 26, 2020
primary completion
Sep 15, 2022
completion
Sep 15, 2022
last updated
Mar 25, 2024
official title
A PHASE 2b TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MenABCWY IN HEALTHY INFANTS 2 AND 6 MONTHS OF AGE
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol